Intellia Therapeutics (NTLA) Operating Leases (2019 - 2026)

Intellia Therapeutics (NTLA) has 8 years of Operating Leases data on file, last reported at $61.4 million in Q1 2026.

• Operating Leases for Q1 2026 came in at $61.4 million, down 23.72% year-over-year; the trailing twelve-month figure through Mar 2026 was $61.4 million (down 23.72% YoY), and the FY2025 annual result was $66.8 million, down 64.81% from the prior year.
• Operating Leases declined to $61.4 million in Q1 2026 per NTLA's latest filing, from $66.8 million in the prior quarter.
• Over five years, Operating Leases peaked at $190.0 million in Q4 2024 and troughed at $60.0 million in Q2 2022.
• A 5-year average of $90.6 million and a median of $84.1 million in 2022 frame the typical range for Operating Leases.
• The sharpest annual moves came in 2024 and 2025: Operating Leases surged 96.34% in 2024, then tumbled 64.81% in 2025.
• A 5-year view of Operating Leases shows it stood at $114.0 million in 2022, then slipped by 15.15% to $96.7 million in 2023, then jumped by 96.34% to $190.0 million in 2024, then plunged by 64.81% to $66.8 million in 2025, then fell by 8.16% to $61.4 million in 2026.
• Business Quant data shows NTLA's Operating Leases at $61.4 million in Q1 2026, $66.8 million in Q4 2025, and $70.6 million in Q3 2025.